The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.
Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
The omega-3 fatty acid icosapent ethyl lowered the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization or unstable angina by as much as 25 percent in a group of patients enrolled in a five-year clinical trial, according to researchers reporting in the Jan. 9 issue of the New England Journal of Medicine.
The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.
A high consumption of ultra-processed foods (i.e. almost any consumable food item, except fresh fruits and vegetables) is associated with an increased risk of cardiovascular disease and mortality, show two studies in BMJ.
Thyroid hormones have a wide range of effects of the cardiovascular system. Too much or too little thyroiid hormones can induce or exacerbate existing cardiovascular disorders. In this article, we highlight the treatment recommendations for thyroid-related CVD events.
How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.